Antonio Ceriello, Italy

IRCCS MultiMedica Cardiovascular and Metabolic Diseases
Professor Antonio Ceriello is Research Consultant at the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain and Research Consultant at IRCCS MultiMedica, Milan, Italy. Professor Ceriello has published widely in the area of diabetes with over 450 original papers and several book chapters. His current h-index is 86. Prof. Ceriello has been consultant of the National Institutes of Health, U.S.A. for the program of the research 2003-2005, related to cardiovascular disease and type 1 diabetes, and member of the writing committee of the American Heart Association of the guidelines on “Acute Hyperglycemia and Acute Coronary Syndromes”. He has also chaired the International Diabetes Federation (IDF) committee for the development in 2008, and in the 2011 for the update of “Guideline for Management of Postmeal Glucose ”. Currently, is the President of the European Association for the Study of Diabetes (EASD) Study Group on “Diabetes and Cardiovascular Diseases”. He also served as Review of the 2012 “European Guidelines on Cardiovascular Disease Prevention in Clinical Practice” and for the 2013 “European Society of Cardiology (ESC) guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD “. He has also been a Member of the Board for the development of the “2019 European Society of Cardiology (ESC) guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD “. Actually he is involved as Expert in the ESC 2020-2022 program for the training of the European cardiologists on the use of the new antidiabetic drugs. From 2009 to 2012 he has been member of the Board of the IDF Europe and Consultant of the EU Commission for the Framework “Diabetes as a model of chronic care management”. He served as Referee of the European Commission for the 2017 grant program regarding diabetes of the HORIZON 2020 Program. He also served as Associate Editor of “Diabetes Care” from 2003 to 2011 and Associate Editor of “Diabetic Medicine” from 2005 to 2016. From July 1st 2016 he has been appointed as Editor in Chief of “Diabetes Research and Clinical Practice”, the official IDF journal. Currently he is also in the Editorial Board of “Cardiovascular Diabetology”. Prof. Ceriello is the winner in the 1984 of the “Italian Annual Award for Young Researcher”, in the 1990 of the “National Award for Research on the Pathophysiology of Diabetic Complications”, in the 1998 of the “National Award Italian Society of Diabetology”, in the 2004 of the “Camillo Golgi Prize” of the EASD and in the 2017 of the “Hellmut Mehnert Award”, during the IDF 2017 Meeting.

Moderator of 1 Session

PARALLEL SESSION Webcast
Session Type
PARALLEL SESSION
Channel
Paris
Date
22.02.2020, Saturday
Session Time
10:30 - 12:00

Presenter of 1 Presentation

Glucose variability as a risk factor for complications in diabetes

Session Type
PARALLEL SESSION
Date
20.02.2020, Thursday
Session Time
13:00 - 14:30
Channel
Madrid
Lecture Time
13:00 - 13:20

Abstract

Abstract Body

Glucose variability (GV) has emerged as an important component of dysglycaemia.

GV is an independent risk factor for diabetic complications, macro- and micro-vascular. Both short- and long-term GV has also an important role in precipitating and accelerating hypoglycaemia and consequently adverse cardiovascular outcomes.

Methods

Currently several indices of GV are being proposed for its evaluation in clinical practice.

Results

To assess short term, within-day GV, the coefficient of variation might be a simple and useful tool for separating stable from labile glycaemic control with a cut-off value of 36%. In contrast, longer-term GV can be defined based on quarterly visit-to-visit measurements of HbA1c, fasting or post-prandial glucose.

Conclusions

Meanwhile, a number of therapeutic strategies, both non-pharmacological (continuous glucose monitoring and life style changes) and pharmacological (GLP-1 receptor agonists, SGLT-2 inhibitors, new long acting insulins and also their fixed combinations with GLP-1 receptor agonists) are available to address this challenging aspect of diabetes management.

Hide